Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma

Trial Profile

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CS 1001 (Primary)
  • Indications T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CStone Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2019 Interim results (data cut off: 17 June 2019; n=29) evaluating CS1001 monotherapy in rr-ENKTL released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 06 Nov 2019 According to an CStone Pharmaceuticals, the abstract content to be presented at ASH 2019 was published online at ASH's official website yesterday.
    • 06 Nov 2019 According to an CStone Pharmaceuticals, as of June 17, 2019, a total of 29 patients were enrolled in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top